Veracyte (VCYT) Stock Forecast & Price Target

Veracyte is positioned for durable fundamental outperformance because its core Afirma and Decipher franchises are still underpenetrated, with management targeting about 80% long-term penetration and both products supported by guideline inclusion, strong real-world evidence, and expanding reimbursed indications. The company has compounded revenue by more than 10x over 2015-2025E, generated $517.2M of revenue in FY2025, and delivered 27.56% adjusted EBITDA margins with $136.3M of operating cash flow, $439.1M of cash, and zero debt as of March 31, 2026. Its outlook is further strengthened by a capital-efficient pipeline and acquisitions, including TrueMRD, Prosigna, and Convergent, which broaden the addressable market across bladder, breast, and other cancers while preserving self-funded growth and operating leverage.

Veracyte is vulnerable to slowing growth because revenue is concentrated in Decipher and Afirma, while Afirma’s mature thyroid market grows only low-single digits and has penetrated just ~38% of its ~180,000-patient addressable pool, suggesting adoption may stall before meaningful new indications emerge. Reimbursement and payer concentration add pressure, as Medicare reached ~20% of FY2025 revenue and UnitedHealthcare ~14%, leaving the company exposed to lab benefit managers, prior authorization, and possible CMS/MolDX or PAMA changes that can hurt volume, pricing, and margins. At the same time, competitive threats, commercialization risk in pipeline programs, and a 53% jump in Q1 2026 R&D to $27.1M for software, trials, and validation point to rising costs and a real chance of weaker-than-expected sales, earnings, and free cash flow.